Healthcare Industry News: Cutaneous T-Cell Lymphoma
News Release - July 18, 2011
Yaupon Therapeutics, Inc. Appoints New Management TeamNew management to focus on NDA submission for proprietary gel formulation of mechlorethamine hydrochloride to treat early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma
MALVERN, Pa.--(Healthcare Sales & Marketing Network)-- Yaupon Therapeutics, Inc., a privately held specialty pharmaceutical company, announced today the appointment of nine new management team members. The new management team will strengthen the company’s foundation and drive momentum as it prepares the NDA submission for its propriety gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma (CTCL).
Steve Tullman, Yaupon Chairman and CEO, was recently chosen to lead the company during this pivotal time. Mr. Tullman has a proven track record in the industry and is known for his ability to advance biotechnology companies while building value for shareholders. Mr. Tullman also serves as the Chairman of Vicept Therapeutics, Inc. and was most recently the co-founder, President and CEO of Ception Therapeutics, Inc. which was acquired by Cephalon, Inc. in April 2010. The majority of the new management team, detailed below, served in leadership positions with Mr. Tullman at Ception.
Tim Henkel, M.D., Ph.D., Appointed Executive Vice President, Head of Research and Development, Yaupon. Previously, Dr. Henkel served as the Executive Vice President of Research and Development at Ception Therapeutics, as Chief Medical Officer of Vicuron Pharmaceuticals (acquired by Pfizer) and as a Vice President at GlaxoSmithKline.
Doug Gessl, Appointed Chief Operating Officer and Chief Financial Officer, Yaupon. Previously, Mr. Gessl was Chief Financial Officer of Ception Therapeutics, and a Senior Vice President with Einhorn Associates. He acted as financial advisor and lead negotiator for Fulcrum Pharmaceuticals, Inc., a legacy company to Ception.
H. Jeffrey Wilkins, M.D., Appointed Chief Medical Officer, Yaupon. Prior to joining Yaupon Therapeutics, Dr. Wilkins served as Vice President of Worldwide Clinical Development: Oncology and Immunology of Cephalon and Senior Vice President of Clinical Development of Ception Therapeutics. He entered the pharmaceutical industry joining GlaxoSmithKline after ten years as a family medicine physician and CEO of a large multi-center group, TriValley Primary Care.
Rounding out the new management team:
* Evan Dick, Ph.D., Senior Vice President of Business Development
* Kelly Copeland, Vice President of Product Strategy
* Jim Dowell, Ph.D., Vice President of Biopharmaceutics
* Jeffrey Shaver, Ph.D., Vice President of Project Management and Operations
* Martin Stogniew, Ph.D., Vice President of Pharmaceutical Sciences
* Lisa Wittmer, Ph.D., Vice President of Regulatory Affairs
“We are focused on the preparation of the NDA submission for Yaupon’s first product. To complete this important task we gathered a highly experienced management team who work well together and deliver accurate results quickly,” said Yaupon Chairman and CEO Steve Tullman. “This team brings together diverse and proven clinical, regulatory and commercialization expertise that will help drive Yaupon to the next level.”
About Yaupon Therapeutics
Yaupon Therapeutics, a privately held, specialty pharmaceutical company, is developing a proprietary gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma (CTCL). Based upon results of a recently completed trial, Yaupon intends to file a new drug application (NDA) with the Food and Drug Administration (FDA) in 2011. If approved, Yaupon’s investigational drug would be the first topical mechlorethamine gel widely available to relieve the signs and symptoms of this rare cancer. Please visit the new Yaupon website www.yaupontherapeutics.com for more information.
Source: Yaupon Therapeutics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.